MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
CAS No. : 2411226-02-1
MCE 国际站:BET bromodomain inhibitor 1
产品活性:BET bromodomain inhibitor 1 是一种具有口服活性的,选择性 BET 溴结构域抑制剂,对 BRD4 的 IC50 为 2.6 nM。BET bromodomain inhibitor 1 与 BRD2(2),BRD3(2),BRD4(1),BRD4(2) 和 BRDT(2) 高亲和力结合 (Kd 值分别为 1.3 nM、1.0 nM、3.0 nM、1.6 nM、2.1 nM)。BET bromodomain inhibitor 1 具有抗癌活性。
研究领域:Epigenetics
作用靶点:Epigenetic Reader Domain
In Vitro: BET bromodomain inhibitor 1 (compound 38; 31.25-125 nM; 24 hours) leads to more pronounced G1-phase cell cycle arrest.
BET bromodomain inhibitor 1 (31.25-500 nM; 6 or 24 hours) is highly effective in inducing dose-dependent inhibition on c-Myc expression and upregulation of p21 levels.
BET bromodomain inhibitor 1 (31.25-125 nM; 6 hours) robustly reduces the expressions of c-Myc, BCL-2, and CDK6.
BET bromodomain inhibitor 1 does not inhibit five cytochrome P450 enzymes (IC50>20 μM).
BET bromodomain inhibitor 1 demonstrates an excellent selectivity for the BET bromodomain family over other bromodomains, with an ∼1500-fold selectivity for BRD4(1) over EP300 (IC50=3857 nM).
BET bromodomain inhibitor 1 strongly inhibited the growth of acute myeloid leukemia cell line MV4-11, acute leukemia cell lines Kasumi-1 and RS-4-11, and multiple myeloma cancer cell line MM1.S cells with IC50 values of 2.4, 4.8, 17.6 and 15.1 nM, respectively.
In Vivo: BET bromodomain inhibitor 1 (compound 38; 6.25, 12.5 mg/kg; PO; daily ; for 28 days) exhibits stronger antitumor activities and completely inhibits the growth of tumor with a tumor growth inhibition (TGI) of 99.7% at 12.5 mg/kg.
BET bromodomain inhibitor 1 (1 mg/kg; IV) has a T1/2 of 1.3 and 0.9 hours, a CL of 21.5 and 15.3 mL/min•kg, and a Vss of 1464 and 782 mL/kg for rats and mouse, respectively.
BET bromodomain inhibitor 1 (3 mg/kg; PO) has a T1/2 of 3.6 hours, a Cmax of 159 ng/mL and an AUC of 884 ng•h/mL for rats.
BET bromodomain inhibitor 1 (1.3 mg/kg; PO) has a T1/2 of 1.3 hours, a Cmax of 399 ng/mL and an AUC of 1710 ng•h/mL for mouse.
相关产品:Bioactive Compound Library Plus | Epigenetics Compound Library | Histone Modification Research Compound Library | Anti-Cancer Compound Library | Reprogramming Compound Library | Orally Active Compound Library | Anti-Blood Cancer Compound Library | Heterocyclic Compound Library | Highly Selective Inhibitors Library | BRD4 Inhibitor-18 | ACBI2 | BI01826025 | Curcumin | GSK6853 | MI-1 | GSK 4027 | ZL0590 | BRD4 Inhibitor-26 | Apabetalone | PROTAC BRD2/BRD4 degrader-1 | MS645 | OF-1 | I-CBP112 | BRM/BRG1 ATP Inhibitor-2 | UMB-32 | Ziftomenib | GSK761 | XX-650-23 | KB02-JQ1 | CD235 | I-BET151 | VZ185 | BET-IN-6 | PLK1/BRD4-IN-1 | MI-136 | SF2523 | SNIPER(BRD)-1 | Anacardic Acid
热门产品线:重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物 | 寡核苷酸 | 抗体 | 点击化学
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides | Antibodies | Click Chemistry
品牌介绍:
• MCE (MedChemExpress) 拥有200 多种全球独家化合物库,我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物;
• 50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领;
• 产品种类涵盖各种重组蛋白,多肽,常用试剂盒 ,更有 PROTAC、ADC 等特色产品,广泛应用于新药研发、生命科学等科研项目;
• 提供虚拟筛选,离子通道筛选,代谢组学分析检测分析,药物筛选等专业技术服务;
• 设有专业的实验中心和严格的质控、验证体系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告,确保产品的高纯度、高品质;
• 产品的生物活性多经各国客户实验验证;
• Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果;
• 专业团队跟踪最新的制药及生命科学研究进展,为您提供全球最新的活性化合物;
• 与世界各大制药公司及知名科研机构建立了长期的合作。